STERIS plc (STE) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.91%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.04%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.91% | Research and development expense / revenue. Period ending 2026-06-30. $115.10M ÷ $6.04B × 100 ≈ 1.91% |
| Stock-based compensation / revenue · 12 months | 1.04% | Share-based compensation / revenue. Period ending 2026-06-30. $62.60M ÷ $6.04B × 100 ≈ 1.04% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 115.10M USD | Research and Development Expense |
| Revenue | 6.04B USD | |
| Stock-based compensation | 62.60M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.14B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $115.10M | $6.04B | $62.60M | $1.14B | (m) | 1.91% | 1.04% | (m) | (m) |
| 2026-03-31 | $112.90M | $5.94B | $61.70M | $1.10B | (m) | 1.90% | 1.04% | (m) | (m) |
| 2025-12-31 | $111.75M | $5.83B | $58.60M | $1.00B | (m) | 1.92% | 1.01% | (m) | (m) |
| 2025-09-30 | $109.65M | $5.70B | $58.20M | $973.24M | (m) | 1.92% | 1.02% | (m) | (m) |
| 2025-06-30 | $108.45M | $5.57B | $57.80M | $927.14M | (m) | 1.95% | 1.04% | (m) | (m) |
| 2025-03-31 | $107.65M | $5.46B | $57.40M | $866.64M | (m) | 1.97% | 1.05% | (m) | (m) |
| 2024-12-31 | $107.42M | $5.40B | $56.55M | $870.82M | (m) | 1.99% | 1.05% | (m) | (m) |
| 2024-09-30 | $105.32M | $5.33B | $56.51M | $852.00M | (m) | 1.98% | 1.06% | (m) | (m) |
| 2024-06-30 | $104.56M | $5.23B | $56.42M | $823.89M | $142.38M | 2.00% | 1.08% | 5.79× | Reported |
| 2024-03-31 | $103.68M | $5.14B | $56.53M | $836.12M | $144.35M | 2.02% | 1.10% | 5.79× | Reported |
| 2023-12-31 | $104.85M | $5.41B | $56.68M | $816.30M | $138.88M | 1.94% | 1.05% | 5.88× | Reported |
| 2023-09-30 | $104.45M | $5.23B | $50.73M | $790.94M | $128.49M | 2.00% | 0.97% | 6.16× | Reported |
| 2023-06-30 | $102.33M | $5.09B | $41.57M | $298.67M | $117.68M | 2.01% | 0.82% | 2.54× | Reported |
| 2023-03-31 | $101.58M | $4.96B | $38.95M | $268.19M | $107.99M | 2.05% | 0.79% | 2.48× | Reported |
| 2022-12-31 | $101.29M | $4.78B | $39.61M | $134.64M | $99.13M | 2.12% | 0.83% | 1.36× | Reported |
| 2022-09-30 | $100.60M | $4.78B | $40.26M | $146.77M | $93.54M | 2.11% | 0.84% | 1.57× | Reported |
| 2022-06-30 | $94.50M | $4.77B | $40.02M | $569.69M | $90.45M | 1.98% | 0.84% | 6.30× | Reported |
| 2022-03-31 | $87.94M | $4.59B | $57.66M | $425.62M | $89.59M | 1.92% | 1.26% | 4.75× | Reported |
| 2021-12-31 | $79.36M | $4.25B | $53.95M | $478.02M | $77.94M | 1.87% | 1.27% | 6.13× | Reported |
| 2021-09-30 | $70.98M | $3.85B | $49.98M | $422.12M | $63.87M | 1.84% | 1.30% | 6.61× | Reported |
| 2021-06-30 | $68.29M | $3.41B | $46.60M | $446.88M | $49.50M | 2.00% | 1.37% | 9.03× | Reported |
| 2021-03-31 | $66.33M | $3.11B | $25.97M | $548.37M | $37.18M | 2.13% | 0.84% | 14.75× | Reported |
| 2020-12-31 | $66.04M | $3.06B | $24.87M | $560.06M | $36.63M | 2.16% | 0.81% | 15.29× | Reported |
| 2020-09-30 | $66.09M | $3.02B | $24.44M | $555.42M | $37.55M | 2.19% | 0.81% | 14.79× | Reported |
| 2020-06-30 | $66.19M | $3.00B | $24.24M | $540.89M | $39.33M | 2.20% | 0.81% | 13.75× | Reported |
| 2020-03-31 | $65.55M | $3.03B | $23.81M | $536.97M | $40.28M | 2.16% | 0.79% | 13.33× | Reported |
| 2019-12-31 | $64.20M | $2.98B | $24.47M | $520.09M | $41.70M | 2.16% | 0.82% | 12.47× | Reported |
| 2019-09-30 | $62.88M | $2.90B | $24.30M | $447.28M | $42.77M | 2.17% | 0.84% | 10.46× | Reported |
| 2019-06-30 | $62.40M | $2.84B | $24.27M | $427.13M | $43.72M | 2.20% | 0.85% | 9.77× | Reported |
| 2019-03-31 | $63.04M | $2.78B | $23.96M | $411.46M | $45.02M | 2.27% | 0.86% | 9.14× | Reported |
| 2018-12-31 | (m) | $2.73B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.30B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.65B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $60.78M | $2.62B | $22.19M | $399.88M | $50.63M | 2.32% | 0.85% | 7.90× | Reported |
| 2017-03-31 | $59.40M | $2.61B | $18.79M | $226.21M | $44.52M | 2.27% | 0.72% | 5.08× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |